Serapha Bio to go public via Boundless Bio merger with $230M backing
What's the deal? Boundless Bio (Nasdaq: BOLD) and privately held Serapha Bio have agreed to an all-stock merger that will take Serapha public. The combined company will operate as Serapha Bio and trade on Nasdaq under the ticker "AATD."
Structurally, though, this looks more like a reverse acquisition than a merger of equals: under the agreed terms, pre-merger Boundless Bio shareholders are expected to own just ~3.7% of the combined company, while pre-merger Serapha stockholders (including those joining the pre-closing financings) take ~96.3%. In effect, Serapha is using Boundless Bio's Nasdaq listing as its route to the public market.
Alongside the deal, Serapha has secured $230 million in private investment commitments, co-led by RTW Investments and RA Capital Management. Other participants include Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management, and Eventide Asset Management.
Of that $230 million, roughly $138 million has already been funded through a Series A round. The remaining $92 million is expected to close alongside the merger.
Why now? Serapha's lead programme, SERP-01, is an in vivo base editing therapy targeting the most severe genetic form of Alpha-1 Antitrypsin Deficiency (AATD) — a condition that damages the lungs and liver. Early clinical data show SERP-01 can restore serum AAT to normal levels, giving investors enough proof-of-concept confidence to back the deal.
Serapha licensed the therapy from China-based YolTech Therapeutics in June 2026, paying an upfront cash fee and a minority equity stake. YolTech is also eligible for milestones exceeding $2 billion and tiered royalties on net sales. YolTech retains rights in Greater China and is already enrolling AATD patients in a trial at Renji Hospital in Shanghai.
The combined company's cash at closing — including the $230 million placement — is expected to fund operations into the second half of 2029, enough runway to complete a Phase 2 trial and begin Phase 3 for SERP-01.
What could go wrong? Gene editing therapies face steep regulatory and scientific hurdles. SERP-01's clinical data so far come from an investigator-initiated trial in China, and replicating those results in a US clinical programme is not guaranteed. The deal also requires Boundless Bio shareholder approval and customary closing conditions, either of which could delay or derail it.
Boundless Bio shareholders will receive a cash dividend before closing, but the all-stock structure — and the ~96/4 ownership split — means existing Boundless holders are left with a sliver of the combined company.
The signal: This deal follows a broader pattern of private biotech companies using reverse mergers with Nasdaq-listed shells to access public markets without a traditional IPO — a route that has grown popular as the IPO window has remained narrow for clinical-stage biotechs.
It also reflects sustained investor appetite for gene editing, particularly base editing approaches that promise precise single-letter corrections without the double-strand DNA breaks associated with earlier CRISPR tools. RTW's Roderick Wong called SERP-01 "a potentially best-in-class base editing therapy," signalling that top healthcare funds see differentiation in the asset.
The size of the financing — $230 million for a pre-Phase 2 programme — underscores how much capital elite life sciences investors are willing to deploy when the science looks compelling, even in an otherwise cautious market.
Read more: GlobeNewswire
